Patients treated with myeloablative therapy followed by bone marrow transplantation Filgrastim is administered as an intravenous short-term infusion over 30 minutes or as a subcutaneous or intravenous continuous infusion over 24 hours, in each case after dilution in 20 ml of glucose 50 mg/ ml (5%) solution.
Kummassakin tapauksessa se tulee laimentaa 20 ml: aan glukoosi- infuusioliuosta 50 mg/ ml (5%).